A Study to Investigate the Efficacy and Safety of Efgartigimod PH20 SC in Adult Participants With Active Idiopathic Inflammatory Myopathy.

NCT05523167 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

265

Enrollment

INDUSTRY

Sponsor class

Conditions

Active Idiopathic Inflammatory Myopathy
Myositis
Dermatomyositis
Polymyositis
Immune-Mediated Necrotizing Myopathy
Antisynthetase Syndrome

Interventions

BIOLOGICAL: EFG PH20 SC
OTHER: PBO

Sponsor

argenx